A: AUTO MODE

Auto Mode: Self-adjusting basal every 5 minutes to help your patients stay in healthy glucose ranges.*

4 Things to Assess for Success:

- Time in Range: ≥ 70%
- Time in Auto Mode: ≥ 80%
- Sensor Wear: ≥ 85%
- Time Below Range: <4 % time below 70 mg/dL
  <1 % time below 54 mg/dL

B: BEHAVIORS

Meal Bolus:
- Ensure patient is bolusing BEFORE meals for best system performance

Correction Bolus:
- Look for patient delivering pump-recommended correction boluses
- Look for phantom carb boluses and discourage patient from entering phantom carb to lower glucose faster as this may cause lows

Calibration:
- Ensure the patient calibrates the sensor 2-3 times daily, this keeps the sensor accurate and helps keep patient in SmartGuard™ Auto Mode

Following-up:
- Instruct patient to download to CareLink™ software regularly at home or at office
- Set realistic expectations that follow-up may be more frequent the first few weeks when beginning SmartGuard™ Auto Mode

C: CLINICIAN CHANGES

- Optimize carb ratios
- Look for post meal highs or lows using CareLink™ system reports
- Adjust insulin to carb ratio by 10-20% as needed
- Adjust Manual Mode settings as needed, see reverse side
THE ABCs OF MANAGING SMARTGUARD™ AUTO MODE
CareLink™ report interpretation made simple

BEST PRACTICES FOR MANUAL MODE SETTINGS ADJUSTMENTS:
Once Auto Mode is initiated, the strategy for adjusting Manual Mode settings is to mirror Auto Mode settings as much as possible.

**Bolus Wizard™ BG Target:**
- 100-150 mg/dL

**Insulin Sensitivity Factor:**
- Calculate ISF using the 1800 Rule = 1800/TDD

**Basal Rates:**
Take the average daily Auto Basal total (found in Statistics section of Assessment & Progress Report) and use one of these methods:
- Divide Auto Basal total by 24 hours and set one basal rate for Manual Mode
- Modify current Manual Mode basal rates proportionally to ensure the sum does not exceed Auto Basal’s total
- If lows occur while in Manual Mode, decrease basal rate(s) by 10-20%

To avoid lows when Auto Mode exits occur, best practice is to evaluate your patient’s Manual Mode settings at each visit.

*Refers to Auto Mode. Some user interaction required. Individual results may vary.

**IMPORTANT SAFETY INFORMATION: MINIMED™ 670G SYSTEM**
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR® NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR® NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results obtained on the CONTOUR® NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

**WARNING:** Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

**IMPORTANT SAFETY INFORMATION: CARELINK™ SOFTWARE**
The CareLink™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult http://www.medtronicdiabetes.com/ImportantSafetyInformation and the appropriate CareLink™ User Guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.

940M20403-011 15MAR2019 © 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.